Remission of lupus nephritis: the trajectory of histological response in successfully treated patients

被引:8
|
作者
Malvar, Ana [1 ]
Alberton, Valeria [1 ]
Lococo, Bruno [1 ]
Lourenco, Maria [1 ]
Martinez, Joaquin [1 ]
Burna, Lucrecia [1 ]
Besso, Celeste [1 ]
Navarro, Jordi [1 ]
Nagaraja, Haikady N. [2 ]
Khatiwada, Aastha [3 ]
Wolf, Bethany [4 ]
Rovin, Brad [5 ]
机构
[1] Hosp Fernandez, Nephrol Unit, Buenos Aires, Argentina
[2] Ohio State Univ, Coll Publ Hlth, Div Biostat, Columbus, OH USA
[3] Natl Jewish Hlth, Dept Biostat & Bioinformat, Denver, CO USA
[4] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA
[5] Ohio State Univ, Wexner Med Ctr, Internal Med Nephrol, Columbus, OH 43210 USA
来源
LUPUS SCIENCE & MEDICINE | 2023年 / 10卷 / 01期
关键词
lupus nephritis; inflammation; autoimmune diseases; CLASSIFICATION; INCIDENT;
D O I
10.1136/lupus-2023-000932
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveThis study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment.MethodsPatients with proliferative +/- membranous LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6-15) months and protocol biopsy 3 (Bx3) at 42 (28-67) months. Kidney histological activity and chronicity indices (AI, CI) were measured.ResultsAI declined in a biphasic fashion, falling rapidly between Bx1 and Bx2 and then more slowly between Bx2 and Bx3. Patients were divided into those who achieved histological remission, defined as an AI=0 at Bx3 (group 1), and those with persistent histological activity (AI >0) at Bx3 (group 2). The early decline in AI was 1.6 times greater (95% CI 1.30, 1.91) in group 1 than group 2 (p=0.01). Between Bx2 and Bx3, the AI decline was 2.19-fold greater (95% CI 2.09, 2.29) in group 1 versus group 2 (p=7.34x10(-5)). Individual histological components of the AI resolved at different rates. Inflammatory lesions like glomerular crescents, karyorrhexis and necrosis mostly resolved by Bx2, whereas endocapillary hypercellularity, subendothelial hyaline deposits and interstitial inflammation resolved slowly, accounting for residual histological activity at biopsy 3 in group 2. In contrast, CI increased rapidly, by 0.15 units/month between Bx1 and Bx2, then plateaued. There were no differences in the rate of accumulation of chronic damage between group 1 and group 2. The increase in CI was significantly related to the severity of glomerular crescents (p=0.044), subendothelial hyaline deposits (p=0.002) and interstitial inflammation (p=0.015) at Bx1.ConclusionsLN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression. Despite responding, LN kidneys accrue chronic damage early during treatment. This finding provides an explanation for the association of chronic progressive kidney disease with recurrent episodes of LN.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis
    Kagawa, Hidetoshi
    Hiromasa, Tsutomu
    Hara, Takayuki
    Takaki, Ayako
    Yamanaka, Ryutaro
    Sada, Ken-ei
    Makino, Hirofumi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (05) : 760 - 766
  • [2] Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis
    Hidetoshi Kagawa
    Tsutomu Hiromasa
    Takayuki Hara
    Ayako Takaki
    Ryutaro Yamanaka
    Ken-ei Sada
    Hirofumi Makino
    Clinical and Experimental Nephrology, 2012, 16 : 760 - 766
  • [3] PROLONGED REMISSION IN PATIENTS WITH LUPUS NEPHRITIS
    Monova, Daniela
    Monov, Simeon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [4] PROLONGED REMISSION IN PATIENTS WITH LUPUS NEPHRITIS
    Monov, S.
    Monova, D.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 41 - 41
  • [5] Rituximab-refractory lupus nephritis successfully treated with belimumab
    Gonzalez-Echavarri, C.
    Ugarte, A.
    Ruiz-Irastorza, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (02) : 355 - 356
  • [6] Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
    Ioannidis, JPA
    Boki, KA
    Katsorida, ME
    Drosos, AA
    Skopouli, FN
    Boletis, JN
    Moutsopoulos, HM
    KIDNEY INTERNATIONAL, 2000, 57 (01) : 258 - 264
  • [7] Pediatric Systemic Lupus Erythematosus and Lupus Nephritis Successfully Treated with Rituximab: A Case Series
    Pradhan, Swetalina
    Dash, Gaurav
    INDIAN JOURNAL OF PAEDIATRIC DERMATOLOGY, 2024, 25 (03) : 213 - 216
  • [8] Histopathological and clinical response in proliferative lupus nephritis patients treated with rituximab
    Gunnarsson, Iva
    Jonsdottir, Thorunn
    Sundelin, Birgitta
    Jacobson, Stefan
    van Vollenhoven, Ronald
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 11 - 12
  • [9] Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis
    Das, Uttara
    Patel, Ravi
    Guditi, Swarnalatha
    Taduri, Gangadhar
    LUPUS, 2021, 30 (06) : 876 - 883
  • [10] Sustained remission of lupus nephritis
    Barber, CEH
    Geldenhuys, L
    Hanly, JG
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 375 - 375